United Therapeutics (NASDAQ:UTHR) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday, BidAskClub reports.

Other research analysts also recently issued research reports about the stock. UBS Group set a $25.00 price objective on shares of Macy’s and gave the stock a “hold” rating in a research report on Friday, May 17th. Oppenheimer started coverage on shares of in a research report on Tuesday, April 9th. They issued an “outperform” rating and a $55.00 price objective for the company. ValuEngine upgraded shares of China Southern Airlines from a “sell” rating to a “hold” rating in a research report on Tuesday, June 11th. Wedbush reiterated an “outperform” rating on shares of Purple Innovation in a research report on Wednesday, May 8th. Finally, Cowen reiterated a “hold” rating and issued a $103.00 price objective on shares of United Therapeutics in a research report on Wednesday, May 1st. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company’s stock. United Therapeutics presently has an average rating of “Hold” and an average price target of $129.56.

NASDAQ UTHR opened at $76.13 on Tuesday. The firm has a market capitalization of $3.34 billion, a P/E ratio of 5.69 and a beta of 1.04. The firm’s fifty day simple moving average is $79.98. United Therapeutics has a 1 year low of $75.31 and a 1 year high of $130.00. The company has a quick ratio of 6.84, a current ratio of 7.19 and a debt-to-equity ratio of 0.45.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($13.96). The business had revenue of $362.70 million for the quarter, compared to analyst estimates of $335.72 million. United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The company’s revenue for the quarter was down 6.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.76 earnings per share. As a group, equities analysts predict that United Therapeutics will post -5.03 earnings per share for the current year.

In other news, Director Richard Giltner sold 5,000 shares of the business’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $79.05, for a total transaction of $395,250.00. Following the completion of the sale, the director now owns 5,000 shares of the company’s stock, valued at $395,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Raymond Dwek sold 3,750 shares of the business’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $76.11, for a total transaction of $285,412.50. Following the sale, the director now directly owns 3,750 shares of the company’s stock, valued at approximately $285,412.50. The disclosure for this sale can be found here. Corporate insiders own 8.20% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Unison Advisors LLC purchased a new stake in shares of United Therapeutics during the first quarter worth about $205,000. Nissay Asset Management Corp Japan ADV increased its stake in shares of United Therapeutics by 2.9% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,029 shares of the biotechnology company’s stock worth $590,000 after purchasing an additional 144 shares in the last quarter. Swiss National Bank increased its stake in shares of United Therapeutics by 2.6% during the first quarter. Swiss National Bank now owns 145,200 shares of the biotechnology company’s stock worth $17,042,000 after purchasing an additional 3,700 shares in the last quarter. First Hawaiian Bank increased its stake in shares of United Therapeutics by 313.8% during the first quarter. First Hawaiian Bank now owns 1,200 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 910 shares in the last quarter. Finally, Captrust Financial Advisors increased its stake in shares of United Therapeutics by 384.9% during the fourth quarter. Captrust Financial Advisors now owns 257 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 204 shares in the last quarter. 96.36% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Article: How Buying a Call Option Works

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.